Deep brain stimulation for Alzheimer disease: a decision and cost-effectiveness analysis

Journal of Neurology

Volumn 262, Issue 5, 2015, Pages 1191-1197

  Mirsaeedi Farahani, Keyvan ^a   Halpern, C H ^b   Baltuch, G H ^c   Wolk, D A ^c   Stein, S C ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Alzheimer s disease; Cost effectiveness economic; Decision analysis; Deep brain stimulation; Harm risk (analysis)

Indexed keywords

ALZHEIMER DISEASE; ARTICLE; BRAIN DEPTH STIMULATION; CLINICAL DECISION MAKING; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE COURSE; HUMAN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; QUALITY OF LIFE; AGED; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMICS; FEMALE; MALE; MARKOV CHAIN; PROCEDURES; PSYCHOLOGICAL RATING SCALE; SENSITIVITY AND SPECIFICITY;

AGED; ALZHEIMER DISEASE; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DEEP BRAIN STIMULATION; FEMALE; HUMANS; MALE; MARKOV CHAINS; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; SENSITIVITY AND SPECIFICITY;

EID: 84929838782     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-015-7688-5     Document Type: Article

References (42)

1. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM (2007) Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement 3(3):186–191
2. World Health Organization (WHO) (2012) Dementia cases set to triple by 2050 but still largely ignored. Geneva, Switzerland
3. Prince M, Bryce R, Ferri C (2011) World Alzheimer Report 2011
4. Toft M, Lilleeng B, Ramm-Pettersen J et al (2011) Long-term efficacy and mortality in Parkinson’s disease patients treated with subthalamic stimulation. Mov Disord 26(10):1931–1934
5. Okun MS (2013) Deep-brain stimulation for Parkinson’s disease. N Engl J Med 368(5):483–484
6. Halpern C, Hurtig H, Jaggi J, Grossman M, Won M, Baltuch G (2007) Deep brain stimulation in neurologic disorders. Parkinsonism Relat Disord 13(1):1–16
7. Stephen JH, Halpern CH, Barrios CJ et al (2012) Deep brain stimulation compared with methadone maintenance for the treatment of heroin dependence: a threshold and cost-effectiveness analysis. Addiction 107(3):624–634
8. Pisapia JM, Halpern CH, Williams NN, Wadden TA, Baltuch GH, Stein SC (2010) Deep brain stimulation compared with bariatric surgery for the treatment of morbid obesity: a decision analysis study. Neurosurg Focus 29(2):E15
9. Mayberg HS, Lozano AM, Voon V et al (2005) Deep brain stimulation for treatment-resistant depression. Neuron 45(5):651–660
10. Greenberg BD, Malone DA, Friehs GM et al (2006) Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder. Neuropsychopharmacology 31(11):2384–2393
11. Schlaepfer TE, Cohen MX, Frick C et al (2008) Deep brain stimulation to reward circuitry alleviates anhedonia in refractory major depression. Neuropsychopharmacology 33(2):368–377
12. De Rojas JO, Saunders JA, Luminais C, Hamilton RH, Siegel SJ (2013) Electroencephalographic changes following direct current deep brain stimulation of auditory cortex: a new model for investigating neuromodulation. Neurosurgery 72(2):267–275 (discussion 275)
13. Halpern CH, Tekriwal A, Santollo J et al (2013) Amelioration of binge eating by nucleus accumbens shell deep brain stimulation in mice involves D2 receptor modulation. J Neurosci 33(17):7122–7129
14. Laxton AW, Tang-Wai DF, McAndrews MP et al (2010) A phase I trial of deep brain stimulation of memory circuits in Alzheimer’s disease. Ann Neurol 68(4):521–534
15. Laxton AW, Lozano AM (2012) Deep brain stimulation for the treatment of Alzheimer disease and dementias. World Neurosurg
16. Neumann PJ, Kuntz KM, Leon J et al (1999) Health utilities in Alzheimer’s disease: a cross-sectional study of patients and caregivers. Med Care 37(1):27–32
17. Shearer J, Green C, Ritchie CW, Zajicek JP (2012) Health state values for use in the economic evaluation of treatments for Alzheimer’s disease. Drugs Aging 29(1):31–43
18. Leon J, Cheng CK, Neumann PJ (1998) Alzheimer’s disease care: costs and potential savings. Health Aff (Millwood) 17(6):206–216
19. Oxford Centre for Evidence Based Medicine. Levels of evidence [Internet] (2009). Available from http://www.cebm.net/index.aspx?o=1025
20. Einarson TR (1997) Pharmacoeconomic applications of meta-analysis for single groups using antifungal onychomycosis lacquers as an example. Clin Ther 19(3):559–569 (discussion 538–9)
21. Von Neumann J, Morgenstern O (1944) Theory of games and economic behavior. Princeton University Press, Princeton
22. Gold MR, Siegel JE, Russel LB, Weinstein MC (1996) Cost-effectiveness in health and medicine. Oxford University Press, New York
23. Fox PJ, Kohatsu N, Max W, Arnsberger P (2001) Estimating the costs of caring for people with Alzheimer disease in California: 2000–2040. J Public Health Policy 22(1):88–97
24. Bureau of Labor Statistics at the US Department of Labor. Consumer price index [Internet] (2012). Available from http://www.bls.gov/cpi/
25. Bureau of Labor Statistics at the US Department of Labor. Labor productivity and costs [Internet] (2012). Available from http://www.bls.gov/lpc/
26. Sonnenberg FA, Beck JR (1993) Markov models in medical decision making: a practical guide. Med Decis Making 13(4):322–338
27. Braithwaite RS, Meltzer DO, King JT, Leslie D, Roberts MS (2008) What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care 46(4):349–356
28. Fong TG, Jones RN, Marcantonio ER et al (2012) Adverse outcomes after hospitalization and delirium in persons with Alzheimer disease. Ann Intern Med 156(12):848–856
29. Augustinsson LE, Blennow K, Blomstrand C et al (1997) Intracerebroventricular administration of GM1 ganglioside to presenile Alzheimer patients. Dement Geriatr Cogn Disord 8(1):26–33
30. Golomb J, Wisoff J, Miller DC et al (2000) Alzheimer’s disease comorbidity in normal pressure hydrocephalus: prevalence and shunt response. J Neurol Neurosurg Psychiatry 68(6):778–781
31. Tang JX, Baranov D, Hammond M, Shaw LM, Eckenhoff MF, Eckenhoff RG (2011) Human Alzheimer and inflammation biomarkers after anesthesia and surgery. Anesthesiology 115(4):727–732
32. Neumann PJ, Araki SS, Arcelus A et al (2001) Measuring Alzheimer’s disease progression with transition probabilities: estimates from CERAD. Neurology 57(6):957–964
33. Spackman DE, Kadiyala S, Neumann PJ, Veenstra DL, Sullivan SD (2012) Measuring Alzheimer disease progression with transition probabilities: estimates from NACC-UDS. Curr Alzheimer Res 9(9):1050–1058
34. Mesterton J, Wimo A, By A, Langworth S, Winblad B, Jönsson L (2010) Cross sectional observational study on the societal costs of Alzheimer’s disease. Curr Alzheimer Res 7(4):358–367
35. Lopez-Bastida J, Serrano-Aguilar P, Perestelo-Perez L, Oliva-Moreno J (2006) Social-economic costs and quality of life of Alzheimer disease in the Canary Islands. Spain. Neurology 67(12):2186–2191
36. Jönsson L, Andreasen N, Kilander L et al (2006) Patient- and proxy-reported utility in Alzheimer disease using the EuroQoL. Alzheimer Dis Assoc Disord 20(1):49–55
37. Karlawish JH, Zbrozek A, Kinosian B, Gregory A, Ferguson A, Glick HA (2008) Preference-based quality of life in patients with Alzheimer’s disease. Alzheimers Dement 4(3):193–202
38. Karlawish JH, Zbrozek A, Kinosian B et al (2008) Caregivers’ assessments of preference-based quality of life in Alzheimer’s disease. Alzheimers Dement 4(3):203–211
39. Bhattacharya S, Vogel A, Hansen M-LH, Waldorff FB, Waldemar G (2010) Generic and disease-specific measures of quality of life in patients with mild Alzheimer’s disease. Dement Geriatr Cogn Disord 30(4):327–333
40. Naglie G, Tomlinson G, Tansey C et al (2006) Utility-based quality of life measures in Alzheimer’s disease. Qual Life Res 15(4):631–643
41. Centers for Medicare and Medicaid Services (CMS). CY2012 Physician Fee Schedule [Internet] (2012). Available from http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched/
42. Centers for Medicare and Medicaid Services (CMS). CY2012 Medicare Hospital Prospective Payment System [Internet] (2012). Available from https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/